Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

If it's a target, it's a pan-cancer target: Tissue is not the issue.

Cancer treatment reviews - 1 Apr 2024

Adashek Jacob J, Kato Shumei, Sicklick Jason K, Lippman Scott M, Kurzrock Razelle

Abstract excerpt

Cancer is traditionally diagnosed and treated on the basis of its organ of origin (e.g., lung or colon cancer). However, organ-of-origin diagnostics does not reveal the underlying oncogenic drivers. Fortunately, molecular diagnostics have advanced at a breathtaking pace, and it is increasingly apparent that cancer is a disease of the genome. Hence, we now have multiple genomic biomarker-based, tissue-agnostic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Diagnosis and Treatment
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38522181
DOI: 10.1016/j.ctrv.2024.102721
PMCID: PMC11093268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

If it's a target, it's a pan-cancer target: Tissue is not the issue.PMID 38522181Read ↗

When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age.Semantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Semantic proximity Read ↗

First Tissue-Agnostic Drug Approval IssuedSemantic proximity Read ↗

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsSemantic proximity Read ↗

Considering molecular alterations as pan-cancer tissue-agnostic targetsSemantic proximity Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read ↗

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.Semantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

The Future of Cancer Diagnosis and Treatment: Unlocking the Power of Biomarkers and Personalized Molecular-Targeted TherapiesSemantic proximity Read ↗

Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.